Cost-effectiveness of treatment with triptanes in Spain;Coste-eficacia del tratamiento con triptanes en España

Revista de Neurologia

Volumn 33, Issue 10, 2001, Pages 921-924

  Gracia Naya, Manuel ^a  

^a HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

Author keywords

Almotriptan; Costs; Efficacy; Migraine; Naratriptan; Rizatriptan; Sumatriptan; Triptanes; Zolmitriptan

Indexed keywords

ALMOTRIPTAN; NARATRIPTAN; RIZATRIPTAN; SUMATRIPTAN; ZOLMITRIPTAN;

ARTICLE; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; HUMAN; MIGRAINE; SPAIN;

EID: 0035713375     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.3310.2001325     Document Type: Article

References (42)

1. Epidemiology of headache in a general population. A prevalence study
2. Prevalence of migraine headache in the United States. Relation to age, income, race, and other socio-demographic factors
3. A nationwide survey of migraine in France: Prevalence and clinical features in adults
4. Migraine in the United States: A review of epidemiology and health care
5. Importancia de las cefaleas en las consultas de neurología
6. Estudio español de calidad de vida en migraña (I). Perfil del paciente con migraña que acude a consultas de neurología
7. Impacto y diferencias asistenciales de la migraña con o sin aura en las consultas de neurología
8. Migraine, physical health and psychiatric disorder: A prospective epidemiological study in young adults
9. Migraine and subsequent risk of stroke in the Physicians' Health Study
10. Undiagnosed migraine headaches. A comparison of symptom-based and reported physician diagnosis
11. American migraine study II: Prevalence, burden and health care utilization for migraine in the United States
12. Impact of migraine and tension-type headache on life-style, consulting behaviour, and medication use: A Canadian population survey
13. Healthcare resource and lost labor costs of migraine headache in the US
14. The economic cost of migraine
15. Prevalencia de migraña laboral y su repercusión económica
16. Burden of migraine: Are view of its socioeconomic impact
17. Indirect costs of migraine in a managed care population
18. Measuring the functional status and well-being of patients with migraine headache
19. A randomized, double-blind comparison of sumatriptan and cafergot in the acute treatment of migraine
20. The oral sumatriptan and aspirin plus metoclopramide comparative study group. A study to compare oral sumatriptan with oral aspirin plus oral metoclopramide in the acute treatment of migraine
21. Acute treatment of migraine attacks: Efficacy and safety of a nonsteroidal anti-inflammatory drug, diclofenac-potassium, in comparison to oral sumatriptan and placebo
22. The effectiveness of combined oral lysine acetylsalicylate and metoclopramide compared with oral sumatriptan for migraine
23. Meta-analysis of rizatriptan efficacy
24. Impact of oral sumatriptan on work-place productivity, health-related quality of live, healthcare use, and patient satisfaction with medication in nurses with migraine
25. The economic burden of migraine. The role of the triptans
26. Triptan use and the economic impact of migraine
27. Effect on productivity and quality of life of oral sumatriptan
28. The productivity cost benefit of maxalt 10mg vs. usual migraine therapy in Canada
29. Patient satisfaction with rizatriptan 10 mg vs. other triptans: Head-to-head comparisons
30. How to define the best efficacy parameters for migraine
31. El análisis coste-efectividad en sanidad
32. El análisis coste-beneficio en sanidad
33. Efficacy and adverse events of subcutaneous, oral, and intranasal sumatriptan used for migraine treatment: A systematic review based on number needed to treat
34. A triptan too far?
35. Efficacy and safety and tolerability of naratriptan and sumatriptan
36. The long-term tolerability and efficacy of oral zolmitriptan (Zomig, 311C90) in the acute treatment of migraine. An international study
37. Rizatriptan (MAXALT) for the acute treatment of migraine and migraine recurrence. A placebo-controlled, outpatient study
38. A placebo-controlled crossover study of rizatriptan in the treatment of multiple migraine attacks
39. Advantageous tolerability of oral almotriptan, a new 5- HT1B/1D, agonist compared with sumatriptan 100 mg
40. Consistent efficacy and tolerability of almotriptan in the acute treatment of multiple migraine attacks: Results of a large, randomized, double-blind, placebo-controlled study
41. Comparison of rizatriptan vs. other triptans on a composite measure of efficacy at 2 hours: Freedom from pain and associated symptoms
42. 24-Hour sustained pain-free status after rizatriptan and other triptans: A comparison